<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/32C7B176-E248-4C1E-87A3-FBF1DCB86D95"><gtr:id>32C7B176-E248-4C1E-87A3-FBF1DCB86D95</gtr:id><gtr:name>Orphidia Limited</gtr:name><gtr:address><gtr:line1>14 HEATHFIELD GARDENS</gtr:line1><gtr:city>LONDON</gtr:city><gtr:postCode>NW11 9HX</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/32C7B176-E248-4C1E-87A3-FBF1DCB86D95" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>32C7B176-E248-4C1E-87A3-FBF1DCB86D95</gtr:id><gtr:name>Orphidia Limited</gtr:name><gtr:address><gtr:line1>14 HEATHFIELD GARDENS</gtr:line1><gtr:city>LONDON</gtr:city><gtr:postCode>NW11 9HX</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>21678.0</gtr:offerGrant><gtr:projectCost>36130.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/C15E87F7-0C63-49B1-BF5F-E4A699E827EB"><gtr:id>C15E87F7-0C63-49B1-BF5F-E4A699E827EB</gtr:id><gtr:firstName>Ron</gtr:firstName><gtr:surname>Oren</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=700426"><gtr:id>6BBF7F4B-86F6-42DD-9E8F-4C4FA4E50869</gtr:id><gtr:title>PuMPED - Proving the Market of Point-ofcarE Diagnostics</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>GRD Proof of Market</gtr:grantCategory><gtr:grantReference>700426</gtr:grantReference><gtr:abstractText>Protein biomarkers offer accurate diagnosis of a wide range of conditions but are currently
only available through centralised laboratories. This makes them expensive to the healthcare
system and slow to provide results, delaying the start of treatment and causing unneeded
hardship for patients. Orphidia?s technology replicates the process of the laboratory in one
device, bringing laboratory-accuracy measurement of biomarkers to the point of care. This
will improve the speed of diagnosis and provide earlier treatment to patients, increasing their
rate of recovery. We expect that Orphidia will also provide significant savings to the
healthcare system itself.
In this project we will improve our understanding of the market for Orphidia and the
specification of a successful product. This will take the form of three activities: first we will
prioritise market sectors for entry, based on the companies that are currently active in it and
on emerging technologies from academia. Having identified our primary market we will
invite doctors and biomarker companies to focus groups, in which we will explore how
Orphidia can best accommodate their needs. Finally we will build a health economic model to
calculate the benefit that our customers will derive from Orphidia.
The outcomes of this project will be essential to inform further development of Orphidia?s
technology. They will help us to identify the markets that we should approach first and to
finalise the business case of Orphidia to biomarker companies and clinicians. Based on this
project we will set target specifications for our first product, to show clearly how it addresses
the needs of our customers. Successful delivery of this project will help us to unlock
investment of &amp;pound;200k to support prototype development and a follow-up of &amp;pound;2m for production
of the first Orphidia product.</gtr:abstractText><gtr:fund><gtr:end>2015-01-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2014-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>21678</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">700426</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>